4 Largecap DII Backed High Profit CAGR Stocks to Watch for Future Multibagger Potential: SBI, L&T, Sun Pharma and BHEL

DII backed high profit CAGR stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. SBI, L&T, Sun Pharma and BHEL meet that test, with market caps from Rs 1.61 lakh crore to Rs 8.89 lakh crore and SBI offering the lowest PE of the group at 9.91. Each of these companies has a domestic institutional holding of at least 20 per cent and a four year profit CAGR of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a domestic institutional holding of at least 20 per cent and a four year profit CAGR of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening DII backed high profit CAGR stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 4 November 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are DII Backed High Profit CAGR Stocks and Why Do They Attract Multibagger Interest?

DII backed high profit CAGR stocks are shares of large companies in which domestic funds, insurers and mutual funds together own at least twenty per cent of the business and whose net profit has compounded at fifteen per cent or more a year over four years. The four here cover public sector banking, engineering and construction, pharmaceuticals and heavy electrical equipment.

Domestic funds invest money from Indian savers and study companies in depth, so a large DII stake in a company with a long record of profit growth shows steady local trust in compounding earnings. For DII backed high profit CAGR stocks, both FY26 and the latest quarter showed growth. Whichever way you read DII backed high profit CAGR stocks, the common thread is rising profit backed by complete financial data. For DII backed high profit CAGR stocks, checking each result against the latest quarter matters more than any single ratio. The next sections explain what stands out in each of DII backed high profit CAGR stocks, using FY26 and latest quarter data. Prices move daily, so recheck the figures for DII backed high profit CAGR stocks before you decide.

DII Backed High Profit CAGR Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book

Prices are closing prices as of 4 November 2026. SBI has the lowest PE of the group at 9.91, while L&T posts the highest return on equity at 14.72%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Price to Book	52-Week Range (Rs)
State Bank of India	979	8,88,926	9.91	12.05	14.29%	1.51	877.05 to 1,234.70
Larsen & Toubro	3,944.40	5,42,364	27.63	22.89	14.72%	4.97	3,288.10 to 4,440.00
Sun Pharmaceutical Industries	1,773.40	4,26,127	35.17	36.42	13.74%	5.09	1,583.70 to 2,046.90
Bharat Heavy Electricals	423.85	1,60,832	55.85	45.89	10.76%	6.01	229.54 to 464.00

SBI: 23.72% Profit CAGR Since FY22

State Bank of India is the country's largest lender, with a branch network that reaches every part of India. It reported FY26 total income of Rs 7,12,643.53 crore, up 7.43% year on year, and net profit of Rs 85,168.47 crore, up 7.78%. Net profit has compounded at 23.72% a year since FY22, while total income has grown 15.03% a year.

In the June 2026 quarter, total income rose 7.83% to Rs 1,80,061.86 crore and net profit grew 13.65% to Rs 24,579.04 crore. The share price has gained 94.60% over five years. Foreign investors raised their holding from 9.98% in July 2025 to 10.81% in June 2026. The stock trades at a PE of 9.91 against an industry PE of 12.05, below the sector average, with a return on equity of 14.29%. The dividend yield is 1.80%.

L&T: Five-Year Gain of 104.48%

Larsen & Toubro is the largest engineering and construction company in India, with additional businesses in IT services and infrastructure projects. It reported FY26 revenue of Rs 2,91,635.04 crore, up 12.23% year on year, and net profit of Rs 19,159.40 crore, up 8.32%. Net profit has compounded at 16.81% a year since FY22, while revenue has grown 16.41% a year. Operating margin was 14.13% in FY26.

The stock trades at a PE of 27.63 against an industry PE of 22.89, with a return on equity of 14.72%. In the June 2026 quarter, revenue rose 8.12% to Rs 70,318.47 crore and net profit grew 15.20% to Rs 4,982.85 crore. The share price has gained 104.48% over five years.

Sun Pharma: 35.75% Profit CAGR Since FY22

Sun Pharmaceutical Industries is one of India's largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 111.23% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 35.17 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.

BHEL: 37.73% Profit CAGR Since FY22

Bharat Heavy Electricals is a government-owned maker of power generation, transmission, industrial and transportation equipment. It reported FY26 revenue of Rs 34,589.83 crore, up 20.08% year on year, and net profit of Rs 1,600.26 crore, up 199.73%. Net profit has compounded at 37.73% a year since FY22, while revenue has grown 12.54% a year. Operating margin was 10.18% in FY26. The debt-to-equity ratio is 0.23.

The stock trades at a PE of 55.85 against an industry PE of 45.89. In the September 2026 quarter, revenue rose 24.28% to Rs 9,553.01 crore and net profit grew 118.98% to Rs 820.94 crore. The share price has gained 523.42% over five years and 97.23% over the past year. Domestic institutions raised their holding from 18.62% in September 2025 to 21.88% in September 2026.

DII Backed High Profit CAGR Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these DII backed high profit CAGR stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Total Income (Rs Cr)	Net Profit (Rs Cr)	Income Growth (YoY)	4-Year Income CAGR	4-Year Net Profit CAGR
SBI	7,12,643.53	85,168.47	7.43%	15.03%	23.72%
L&T	2,91,635.04	19,159.40	12.23%	16.41%	16.81%
Sun Pharma	61,673.94	11,564.52	12.69%	11.62%	35.75%
BHEL	34,589.83	1,600.26	20.08%	12.54%	37.73%

Check the Univest Screener for live data on these DII backed high profit CAGR stocks

Institutional Holding in SBI, L&T, Sun Pharma and BHEL

Institutional holding shows who is backing these DII backed high profit CAGR stocks alongside the promoter. The table uses the latest reported quarter for each. L&T has the deepest institutional backing, with FII and DII together holding 62.15% as of June 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%) and BHEL (from 18.62% to 21.88%).

Stock	Promoter	FII	DII	Public	Quarter
SBI	55.47%	10.81%	26.64%	7.08%	June 2026
L&T	Nil	19.13%	43.02%	37.85%	June 2026
Sun Pharma	52.68%	14.36%	22.27%	10.70%	September 2026
BHEL	58.17%	9.94%	21.88%	10.02%	September 2026

Risks to Weigh in DII Backed High Profit CAGR Stocks

Being careful with DII backed high profit CAGR stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: BHEL trades at a PE of 55.85 against an industry PE of 45.89, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between DII Backed High Profit CAGR Stocks

Picking from DII backed high profit CAGR stocks comes down to four checks, applied in order.

1. Check asset quality and net interest margin first, then return on equity and price to book. Debt-to-equity does not apply to lenders.
2. Compare each PE with the industry PE (12.05 to 45.89) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track SBI, L&T, Sun Pharma and BHEL live prices.

Conclusion

Among DII backed high profit CAGR stocks, SBI stands out for the lowest PE of the group at 9.91, L&T for 12.23% revenue growth in FY26, Sun Pharma for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06 and BHEL for the fastest profit growth, 37.73% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing DII backed high profit CAGR stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on DII Backed High Profit CAGR Stocks to Watch

Which are the best DII backed high profit CAGR stocks to watch for multibagger potential?

Ans. SBI, L&T, Sun Pharma and BHEL are the 4 names this list highlights, with market caps of Rs 8,88,926 crore, Rs 5,42,364 crore, Rs 4,26,127 crore and Rs 1,60,832 crore respectively. SBI is notable for the lowest PE of the group at 9.91. L&T stands out for 12.23% revenue growth in FY26. Sun Pharma offers a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. BHEL brings the fastest profit growth, 37.73% a year since FY22. These are watchlist names for DII backed high profit CAGR stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is L&T a good stock for long-term investors?

Ans. L&T has a return on equity of 14.72%, a PE of 27.63 against an industry PE of 22.89 and a market cap of Rs 5,42,364 crore. Net profit has compounded at 16.81% a year since FY22, and FY26 revenue rose 12.23% while June 2026 quarter net profit grew 15.20%. Long-term returns in DII backed high profit CAGR stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can BHEL become a multibagger from here?

Ans. BHEL has already gained 523.42% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in DII backed high profit CAGR stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 37.73% a year since FY22, and FY26 revenue rose 20.08%. At a PE of 55.85 against an industry PE of 45.89, valuation should be checked against that growth before investing.

What is the market cap of SBI, L&T, Sun Pharma and BHEL?

Ans. As of 4 November 2026, SBI has a market cap of Rs 8,88,926 crore, L&T has a market cap of Rs 5,42,364 crore, Sun Pharma has a market cap of Rs 4,26,127 crore and BHEL has a market cap of Rs 1,60,832 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on DII backed high profit CAGR stocks.

What are the risks of investing in DII backed high profit CAGR stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. BHEL trades at a PE of 55.85 against an industry PE of 45.89, so earnings growth needs to hold up.

Why is BHEL trading at a PE of 55.85?

Ans. BHEL's PE of 55.85 compares with an industry PE of 45.89. The market is paying a premium for profit growth of 37.73% a year since FY22, latest-quarter profit growth of 118.98% and FY26 revenue growth of 20.08%, which also means the stock is more sensitive if growth slows. Investors in DII backed high profit CAGR stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in SBI, L&T, Sun Pharma and BHEL?

Ans. As of the latest reported quarter, FII and DII together hold 37.45% of SBI (10.81% and 26.64%), 62.15% of L&T (19.13% and 43.02%), 36.63% of Sun Pharma (14.36% and 22.27%) and 31.82% of BHEL (9.94% and 21.88%). Rising institutional holding is a useful signal in DII backed high profit CAGR stocks, though it should be read with earnings trends rather than on its own.